When comparing IDH1 and IDH2‐mutated AML, we found no significant difference in the magnitude or rate of blast reduction (median log10 fold reduction and log10/day), or OS, consistent with Middeke et al. This evidence concerns the gene IDH2 and acute myeloid leukemia.